 CALGB 100001 was a phase II study evaluating autologous stem cell transplant followed by nonmyeloablative allogeneic stem cell transplant in patients with multiple myeloma who had received no more than 18 months of prior therapy and had experienced no more than 1 prior progression event . Conditioning for ASCT was with high dose melphalan 200 mg m

@highlight CALGB Alliance 100001 evaluated tandem autologous allogeneic transplant for myeloma.
@highlight A fludarabine cyclophosphamide conditioning regimen was associated with a very low treatment related mortality rate.
@highlight Long term follow up demonstrates a subset of patients who derived benefit from this approach.
